A phase I/II study of lenvatinib (LEN) plus everolimus (EVE) in recurrent and refractory pediatric solid tumors, including CNS tumors.

被引：0
|
作者：
Dela Cruz, Filemon S.
Fox, Elizabeth
Muscal, Jodi Ann
Kirov, Ivan
Geller, James I.
DuBois, Steven G.
Kim, AeRang
Croop, James
Laetsch, Theodore Willis
Minard, Charles G.
Liu, Xiaowei
Weigel, Brenda
Okpara, Chinyere E.
Huang, Jie
Dutta, Lea
Aluri, Jagadeesh
Bender, Julia Lynne Glade
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] St Jude Childrens Res Hosp, 332 N Lauderdale St, Memphis, TN 38105 USA
[3] Baylor Coll Med, Houston, TX 77030 USA
[4] CHOC Childrens Hosp, Orange, CA USA
[5] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA
[6] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA
[7] Harvard Med Sch, Boston, MA 02115 USA
[8] Childrens Natl Hosp, Washington, DC USA
[9] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[10] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[11] Childrens Hlth, Dallas, TX USA
[12] Childrens Oncol Grp, Monrovia, CA USA
[13] Univ Minnesota, Minneapolis, MN USA
[14] Eisai Ltd, Hatfield, Herts, England
[15] Eisai Inc, Woodcliff Lake, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10527
引用
收藏
页数：2
相关论文
共 50 条
  • [21] ENTRECTINIB IN CHILDREN AND ADOLESCENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS INCLUDING PRIMARY CNS TUMORS
    Robinson, Giles
    Desai, Ami
    Gauvain, Karen
    Basu, Ellen
    Dorris, Kathleen
    Maese, Luke
    Sabnis, Amit
    Foster, Jennifer
    Shusterman, Suzanne
    Yoon, Janet
    Weiss, Brian
    Abdelbaki, Mohamed
    Farid-Kapadia, Mufiza
    Meneses-Lorente, Georgina
    Cardenas, Alison
    Hutchinson, Katherine
    Bergthold, Guillaume
    Maneval, Edna Chow
    Fox, Elizabeth
    Gajjar, Amar
    NEURO-ONCOLOGY, 2019, 21 : 186 - 186
  • [22] Phase I study of talazoparib and irinotecan in children and young adults with recurrent/refractory solid tumors.
    Federico, Sara Michele
    Stewart, Elizabeth
    Coleman, Jamie L.
    Bishop, Michael William
    Santana, Victor M.
    Lam, Catherine
    Hawkins, Dana
    Wu, Jianrong
    Mao, Shenghua
    Goshorn, David Ross
    Papp, Alberto S.
    Dyer, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Phase I Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
    Morgenstern, Daniel A.
    Marzouki, Monia
    Bartels, Ute
    Irwin, Meredith S.
    Sholler, Giselle L. S.
    Gammon, Janet
    Yankanah, Rosanna
    Wu, Bing
    Samson, Yvan
    Baruchel, Sylvain
    PEDIATRIC BLOOD & CANCER, 2014, 61 (01) : 128 - 133
  • [24] A phase I study of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors.
    McGregor, L. M.
    Spunt, S. L.
    Ward, D.
    Wu, J.
    Billups, C.
    Ivy, S. P.
    Santana, V. M.
    Fouladi, M.
    Furman, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
    Rangwala, Fatima A.
    Bendell, Johanna C.
    Kozloff, Mark
    Arrowood, Christy
    Meadows, Jennifer
    Tourt-Uhlig, Sandra Ellen
    Murphy, Jennifer
    Meadows, Kellen
    Morse, Michael
    Uronis, Hope Elizabeth
    Hsu, Shiaowen David
    Zafar, Yousuf
    Hurwitz, Herbert
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [26] Phase I/II trial of vorinostat in combination with etoposide in pediatric patients with relapsed/refractory solid tumors.
    Trippett, Tanya M.
    Smith, Amy
    Neville, Kathleen
    Chi, Susan
    Narendran, Aru
    Arceci, Robert
    Direnzo, Jennifer
    Gore, Lia
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [27] Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.
    Banwait, Ranjit Singh
    Ko, Heidi Chwan
    Michalek, Joel
    Lathrop, Kate Ida
    Bowhay-Carnes, Elizabeth Ann
    Fotopoulos, Georgios
    Elledge, Richard M.
    Karnad, Anand B.
    Kaklamani, Virginia G.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] A phase II study of sirolimus and erlotinib in recurrent/refractory germ cell tumors.
    Laetsch, Theodore Willis
    Kumar, Kirthi
    Rakheja, Dinesh
    Wickiser, Jonathan E.
    Rodriguez-Galindo, Carlos
    Frazier, A. Lindsay
    Amatruda, James
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [29] Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN plus EVE in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Motzer, Robert
    Hutson, Thomas
    Glen, Hilary
    Michaelson, Dror
    Molina, Ana M.
    Eisen, Timothy
    Jassem, Jacek
    Zolnierek, Jakub
    Maroto, Pablo
    Mellado, Begona
    Melichar, Bohuslav
    Tomasek, Jiri
    Kim, Han-Joo
    Wood, Karen
    Dutcus, Corina
    Larkin, James M. G.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [30] Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE) and LEN plus EVE in metastatic renal cell carcinoma (mRCC)
    Hutson, Thomas E.
    Dutcus, Corina E.
    Ren, Min
    Baig, Mahadi Ali
    Fishman, Mayer N.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345